ahlam1399
08-16-2016, 01:18 AM
BRIEF-Vertex enrollment complete in Phase 3 study in people with two copies of F508DEL mutation
* Provides update on ongoing phase 3 program For VX-661 incombination with ivacaftor for the treatment of cystic fibrosishttp://feeds.feedburner.com/~ff/reuters/companyNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/companyNews?a=iabcPQ-5Ze4:Afu6VGXPmSU:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/companyNews?i=iabcPQ-5Ze4:Afu6VGXPmSU:V_sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/companyNews?a=iabcPQ-5Ze4:Afu6VGXPmSU:V_sGLiPBpWU) http://feeds.feedburner.com/~ff/reuters/companyNews?i=iabcPQ-5Ze4:Afu6VGXPmSU:F7zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/companyNews?a=iabcPQ-5Ze4:Afu6VGXPmSU:F7zBnMyn0Lo)
http://feeds.feedburner.com/~r/reuters/companyNews/~4/iabcPQ-5Ze4
* Provides update on ongoing phase 3 program For VX-661 incombination with ivacaftor for the treatment of cystic fibrosishttp://feeds.feedburner.com/~ff/reuters/companyNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/companyNews?a=iabcPQ-5Ze4:Afu6VGXPmSU:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/companyNews?i=iabcPQ-5Ze4:Afu6VGXPmSU:V_sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/companyNews?a=iabcPQ-5Ze4:Afu6VGXPmSU:V_sGLiPBpWU) http://feeds.feedburner.com/~ff/reuters/companyNews?i=iabcPQ-5Ze4:Afu6VGXPmSU:F7zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/companyNews?a=iabcPQ-5Ze4:Afu6VGXPmSU:F7zBnMyn0Lo)
http://feeds.feedburner.com/~r/reuters/companyNews/~4/iabcPQ-5Ze4